Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more
Sangamo Therapeutics Inc (SGMO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -4.565x
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has a cash flow conversion efficiency ratio of -4.565x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.50 Million) by net assets ($6.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sangamo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Sangamo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sangamo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sangamo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United Pharm
KO:033270
|
0.027x |
|
West Coast Paper Mills Limited
NSE:WSTCSTPAPR
|
0.024x |
|
DOHOME
BK:DOHOME-R
|
N/A |
|
StealthGas Inc
NASDAQ:GASS
|
0.023x |
|
Nantong Xingqiu Graphite Co. Ltd. A
SHG:688633
|
0.024x |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
0.047x |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
N/A |
|
Cornerstone OnDemand Inc
F:8CO
|
0.014x |
Annual Cash Flow Conversion Efficiency for Sangamo Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Sangamo Therapeutics Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.77 Million | $-67.14 Million | -2.949x | -8.70% |
| 2023-12-31 | $82.89 Million | $-224.84 Million | -2.713x | -257.79% |
| 2022-12-31 | $294.96 Million | $-223.63 Million | -0.758x | -22.00% |
| 2021-12-31 | $375.34 Million | $-233.25 Million | -0.621x | -281.95% |
| 2020-12-31 | $497.37 Million | $169.88 Million | 0.342x | +202.35% |
| 2019-12-31 | $432.74 Million | $-144.40 Million | -0.334x | -429.20% |
| 2018-12-31 | $366.52 Million | $37.15 Million | 0.101x | +70.38% |
| 2017-12-31 | $187.90 Million | $11.18 Million | 0.059x | +112.30% |
| 2016-12-31 | $136.19 Million | $-65.88 Million | -0.484x | -176.07% |
| 2015-12-31 | $192.44 Million | $-33.72 Million | -0.175x | -538.01% |
| 2014-12-31 | $206.63 Million | $-5.67 Million | -0.027x | +82.84% |
| 2013-12-31 | $121.71 Million | $-19.48 Million | -0.160x | -28.53% |
| 2012-12-31 | $64.90 Million | $-8.08 Million | -0.125x | +61.46% |
| 2011-12-31 | $80.13 Million | $-25.89 Million | -0.323x | +24.51% |
| 2010-12-31 | $55.91 Million | $-23.93 Million | -0.428x | -400.74% |
| 2009-12-31 | $71.78 Million | $-6.14 Million | -0.085x | +72.69% |
| 2008-12-31 | $55.40 Million | $-17.34 Million | -0.313x | -40.54% |
| 2007-12-31 | $72.12 Million | $-16.07 Million | -0.223x | +25.05% |
| 2006-12-31 | $48.70 Million | $-14.48 Million | -0.297x | -176.25% |
| 2005-12-31 | $37.81 Million | $-4.07 Million | -0.108x | +65.72% |
| 2004-12-31 | $32.38 Million | $-10.16 Million | -0.314x | -88.44% |
| 2003-12-31 | $44.66 Million | $-7.44 Million | -0.167x | +6.57% |
| 2002-12-31 | $54.25 Million | $-9.67 Million | -0.178x | -140.42% |
| 2001-12-31 | $82.35 Million | $-6.11 Million | -0.074x | -102.14% |
| 2000-12-31 | $66.89 Million | $-2.45 Million | -0.037x | +87.92% |
| 1999-12-31 | $7.90 Million | $-2.40 Million | -0.304x | -- |